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Abstract
Background: Opioids are the gold standard for the treatment of acute pain despite serious side effects in the central and
enteric nervous system. m-opioid receptors (MOPs) are expressed and functional at the terminals of sensory axons, when
activated by exogenous or endogenous ligands. However, the presence and function of MOP along nociceptive axons remains
controversial particularly in naı¨ve animals. Here, we characterized axonal MOPs by immunofluorescence, ultrastructural, and
functional analyses. Furthermore, we evaluated hypertonic saline as a possible enhancer of opioid receptor function.
Results: Comparative immunolabeling showed that, among several tested antibodies, which all provided specific MOP detection
in the rat central nervous system (CNS), only one monoclonal MOP-antibody yielded specificity and reproducibility for MOP
detection in the rat peripheral nervous system including the sciatic nerve. Double immunolabeling documented that MOP
immunoreactivity was confined to calcitonin gene-related peptide (CGRP) positive fibers and fiber bundles. Almost identical
labeling and double labeling patterns were found using mcherry-immunolabeling on sciatic nerves of mice producing a MOP-
mcherry fusion protein (MOP-mcherry knock-in mice). Preembedding immunogold electron microscopy on MOP-mcherry
knock-in sciatic nerves indicated presence of MOP in cytoplasm and at membranes of unmyelinated axons. Application of [D-
Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO) or fentanyl dose-dependently inhibited depolarization-induced CGRP release from
rat sciatic nerve axons ex vivo, which was blocked by naloxone. When the lipophilic opioid fentanyl was applied perisciatically in
naı¨ve Wistar rats, mechanical nociceptive thresholds increased. Subthreshold doses of fentanyl or the hydrophilic opioid DAMGO
were only effective if injected together with hypertonic saline. In vitro, using b-arrestin-2/MOP double-transfected human embry-
onic kidney cells, DAMGO as well as fentanyl lead to a recruitment of b-arrestin-2 to the membrane followed by a b-arrestin-2
reappearance in the cytosol and MOP internalization. Pretreatment with hypertonic saline prevented MOP internalization.
Conclusion: MOPs are present and functional in the axonal membrane from naı¨ve animals. Hypertonic saline acutely
decreases ligand-induced internalization of MOP and thereby might improve MOP function. Further studies should explore
potential clinical applications of opioids together with enhancers for regional analgesia.
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Background
m-Opioid receptors (MOPs) are expressed both in the
central and peripheral nervous system where they play
a pivotal role in analgesia. However, systemic applica-
tion for pain treatment has several side eﬀects, like
nausea and respiratory depression as well as tolerance
and addiction.1 In fact, in closed claim studies on
anesthesia-related morbidity and mortality, opioid-
induced respiratory depression is the most important
reason for death or severe brain damage.2 To avoid sys-
temic side eﬀects, peripheral administration of opioids to
selectively target MOP in nociceptors is an alternative.
Peripheral opioid receptors are transcribed in peri-
karya of sensory neurons in the dorsal root ganglion
(DRG) and are transported along the axons to their ter-
minals.3,4 While opioid receptor expression5 and func-
tion has been conclusively demonstrated at nerve
terminals,6–8 it remains controversial whether they are
expressed in the membrane of peripheral nociceptive
axons and whether opioid receptor agonists can induce
antinociception when applied at the axon. Under patho-
logic conditions, e.g. in animals with neuropathy caused
by nerve injury, exogenous as well as endogenous MOP
agonists applied at the damaged nerve can elicit potent
antinociception or anti-allodynia.9–12 In contrast, in
naı¨ve animals, no antinociception to thermal nociceptive
stimuli was seen in rats after application of fentanyl and
morphine alone.13 In clinical settings, hydrophilic and
hydrophobic opioids like morphine, fentanyl, alfentanil,
buprenorphine, and butorphanol have been used not as
sole analgesics but as adjuvants to local anesthetics in
regional anesthesia via application in nerve blocks14 or
via intravenous regional anesthesia using a tourniquet
approach.15 To date, there are still conﬂicting results
whether the addition of opioids to local anesthetics
improves regional anesthesia. No larger clinical studies
have been conducted using opioids alone.
An apparent failure of perineurally injected opioids to
exert antinociception in intact nerves could be caused
either by a lack of functional opioid receptors in the
axonal membranes under physiological conditions, or
by the inability of injected opioids to cross the intact
perineurial barrier and to reach nociceptors. Indeed,
application of the hydrophilic opioid [D-Ala2,
N-MePhe4, Gly-ol]-enkephalin (DAMGO) at the sciatic
nerve in naı¨ve rats elicits mechanical antinociception
when it is accompanied by treatments suited to open
the perineurial barrier, such as coinjection of hypertonic
saline.16–18 This ﬁnding indicates that, under these con-
ditions, axonal MOPs are available and functional.
However, it remains to be determined (1) whether
hypertonic saline-mediated barrier breakdown alone is
suﬃcient to allow opioid-induced antinociception on
MOPs constitutively present in axonal membranes
of nociceptors or (2) whether hypertonic saline treatment
exerts additional inﬂuence directly on MOP availability
and function similar to its eﬀects in non-inﬂamed peri-
pheral tissue.19
MOP activates several signaling cascades including
G(i)-protein-dependent and -independent signaling path-
ways,20 e.g. activation of adenylate cyclase, phosphoryl-
ation by protein kinases, activation of speciﬁc
potassium21 and calcium channels,22 and b-arrestin
recruitment. Following ligand binding, MOP is desensi-
tized, e.g. by phosphorylation indicating an acute loss of
MOP-eﬀector coupling within seconds to minutes.
Desensitization can be followed by internalization of
MOP via b-arrestin as a scaﬀolding molecule.23 After
internalization of MOP, the receptor can be reinserted
as a non-desensitized/reactivated receptor in the plasma
membrane. MOP internalization induced by the agonists
enkephalin or etorphine can be blocked by hypertonic
sucrose.24 Whether this applies to hypertonic saline solu-
tions as well is currently unknown.
To address all of these questions, this study was
designed to analyze the presence and function of
MOPs in nociceptive axons under physiological condi-
tions. Since previous studies had shown very low levels of
MOP in intact peripheral nerves,3 and signiﬁcant unspe-
ciﬁc labeling of polyclonal MOP-antibodies in peripheral
nervous tissue,3 we tested various commercially available
antibodies to achieve optimal MOP detection in rat
sciatic nerve. Additionally, we took advantage of a pre-
viously characterized genetic mouse model with a
knocked-in ﬂuorescent protein tag into the Oprm1 of
MOP25 to perform comparative light and ultrastructural
MOP localization studies with a higher speciﬁcity and
signal-to-noise ratio than achievable using an antibody
against the wild-type (WT) MOP sequence.
Functionality of MOPs in sensory axons was assessed
by studying MOP agonist-triggered inhibition of CGRP
release from isolated sciatic nerve preparations and
in vivo in rats by performing pain behavioral tests after
perisciatic application of the lipophilic opioid fentanyl
without coinjection treatment. Furthermore, the eﬀect
of hypertonicity on opioid-induced antinociception
in vivo or on b-arrestin-2 recruitment and MOP intern-
alization was evaluated in vitro in MOP b-arrestin-2
double-transfected cells.
Material and Methods
Rats, MOP-mcherry knock-in mice
Animal experiments were performed in accordance with
the European Communities Council Directive of 26 May
2010 and approved by the local animal care committees
(Regierung von Unterfranken, Wuerzburg, Germany
and Regierung von Mittelfranken, Ansbach, Germany,
Com’Eth 2010-003 Strasbourg, France). They were
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conducted in accordance with the International
Association for the Study of Pain.26 At the end of the
experiment, animals were sacriﬁced using an intracardial
injection of a solution of T61 (embutramide, mebezo-
nium, and tetracaine) or intracardial perfusion with
4% paraformaldehyde (PFA) both under isoﬂurane
anesthesia according to national guidelines (see below).
Animals were kept at 22C with a light-dark circle of
12 h. Animals had access to food and water ad libitum.
Wistar male rats (Janvier, Saint-Berthevin Cedex,
France), weighing 180–200 g, were used for imaging,
behavior, and CGRP release experiments as described
below.
Male and female homozygous knock-in mice aged six
to 12 weeks were used. MOP-mcherry knock-in mice
were generated by homologous recombination.25 The
mcherry cDNA was introduced into exon 4 of the
MOP gene, in frame and 50 of the stop codon. This
C-terminal construct was designed to allow correct
native-like MOP expression at subcellular level to visu-
alize the MOP protein expressing neuronal population.
The genetic background of all mice was C57/
BL6J;129svPas (50:50%). Functional properties of
MOP are maintained in MOP-mcherry mice both
in vitro and in vivo.25
Genotyping
Mice genotyping was performed by standard PCR tech-
nique using a 50 oligonucleotide located on the fourth
exon of the oprm1 gene (BAZ 43 tgacgtgacatgcagttga-
gattt, Euroﬁns) and a 30 oligonucleotide located in the 30
untranslated region (BAZ 44 tcccacaaaccctgacagcaac,
Euroﬁns). Introduction of the coding sequence for
mcherry increased the size of the ampliﬁed fragment by
about 800 bp enabling identiﬁcation of WT oprm1 -/-,
heterozygous oprm1 -/mch, and homozygous oprm1
mch/mch (MOP-mcherry knock-in) animals by PCR.
Ear samples were analyzed as described before.25
Immunofluorescence
Rats and mice were perfused under deep isoﬂurane anes-
thesia via the left ventricle. A brief prerinse with hepar-
inized saline was followed by ﬁxation (4% PFA in 0.1M
phosphate buﬀer (pH 7.4)) and a postﬁxation over night
at 4C. Subsequently, tissues were dissected, cryopro-
tected with 10% and 20% sucrose in 0.01M phos-
phate-buﬀered saline (PBS), embedded in O.C.T.
(O.C.T. Compound, code 4583, Tissue-Tek, Sakura),
frozen in liquid nitrogen-cooled 2-methylbutane, and
stored at 80C until use. Frozen tissue was sectioned
in 10 mm cryosections (cryostat CM 3050 S, Leica) and
collected on glass slides (SuperfrostTM Plus Microscope
Slides, code J1800AMNZ, Thermo Scientiﬁc) or cut at
30 mm and collected in a 24-well plate in PBS (free-
ﬂoating section). Free-ﬂoating sections were used imme-
diately after cutting; cryostat sections on glass slides were
immediately used or stored at 80C.
Immunostaining was performed on brain, spinal cord,
DRG, and sciatic nerve. Cryostat sections from rat tissue
were washed in PBS followed by blocking in PBS/
0.5% Triton-X-100/5% normal goat serum for 2 h.
Subsequently, primary antibody incubation was carried
out overnight at 4C in PBS/0.5% Triton X-100/1%
normal goat serum using the appropriate concentration
of one or, for dual labeling, two antibodies from diﬀer-
ent species (rabbit-anti-MOP (MOP_1), polyclonal,
#ab10275, 1:500–1:800, Abcam, Cambridge, UK;
rabbit-anti-MOP (MOP_2), polyclonal, #RA10104,
1:600–1:800, Neuromics, Edina, MN, USA; guinea
pig-anti-MOP, polyclonal, #ab64746, Abcam; guinea
pig-anti-MOP, polyclonal, #GP10106, Neuromics;
rabbit-anti-MOP, monoclonal, #ab134054, 1:250–500,
(RabMAb-MOP), Abcam; mouse-anti-CGRP, monoclo-
nal, #ab81887, 1:400, Abcam). Free-ﬂoating sections
were kept in slight movement. Then, samples were
washed in PBS and incubated for 2 h at room tempera-
ture with appropriate secondary antibody or combin-
ation of antibodies (Cy3-labeled anti-rabbit, 1:400–800,
Cy2-labeled anti-mouse, 1:400; Jackson Immuno
Research, West Grove, PA, USA), treated for nuclear
counterstain with 40,6-diamidino-2-phenylindole
(DAPI) and mounted with mounting medium
(Fluorogel, #17985–11, Electron Microscopy Sciences).
Controls (omission of one or both primary antibodies)
were carried along for each immunolabeling experiment.
In dual labeling, cross reactivity controls treated with
only one of the two primary antibodies but both second-
ary antibodies were also performed. All controls lacked
speciﬁc staining.
Immunoﬂuorescence on mouse tissue was carried out
on cryosections as described,25 with overnight incubation
at 4C using rabbit-anti-mcherry antibody (DsRed;
#632496, 1:1000, Clontech, Mountain View, CA, USA)
alone or in combination with anti-CGRP (see above).
Free-ﬂoating sections were kept in slight movement.
No speciﬁc labeling was found after omission of primary
antibodies in all tissue samples from WT and homozy-
gous MOP-mcherry knock-in mice. Labeling was also
absent in brain sections of WT mice incubated with the
anti-mcherry antibody. Observation and image acquisi-
tion was done with the BZ-9000 BIOREVO (Keyence) or
an Olympus BHS epiﬂuorescence microscope equipped
with the appropriate ﬁlter systems.
Electron microscopy
Preembedding immunogold labeling of sciatic nerve. After per-
fusion, overnight postﬁxation, and washing steps as
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described above, sciatic nerve from rat, MOP-mcherry
knock-in and WT mice were coronally cut into small
pieces (3mm). Immunolabeling was carried out with
RabMAb-MOP for rat and anti-mcherry antibody for
mouse preparations and detected using ultrasmall gold-
conjugated secondary antibodies (goat-anti-rabbit US,
#100.011, 1:50, Aurion, Wageningen, Netherlands) and
silver-enhancement according to Bonn et al.27 Control
incubations included omission of primary antibody
and incubation of WT mouse sciatic nerve with and
without mcherry antibody. After labeling, prepar-
ations were osmicated, dehydrated in ethanol, and
embedded in Epon.27 Serial coronal ultrathin sections
(70 nm) were cut at 5 mm from the surface, collected
onto 500 mesh formvar-coated nickel grids, contrasted
with uranyl acetate and lead citrate,28 and observed
with the transmission electron microscope LEO AB
912 (Zeiss NTS, Oberkochen, Germany). Micrographs
of Remak bundles and myelinated axons were taken at
6300magniﬁcation using a CCD camera (Sharp:eye
CCD camera controller und TEM-camera, TRS
Tro¨ndle, Germany).
Analysis of immunogold labeling. Individual Remak bun-
dles and myelinated axons in their vicinity were
identiﬁed in micrographs of serial ultrathin sections
of the following preparations: MOP-mcherry knock-
in mouse sciatic nerve reacted with/without mcherry
antibody (MOP-mcherry pos/neg); WT mouse sciatic
nerve reacted with/without mcherry antibody (WT-
pos/neg). For each identiﬁed Remak bundle, micro-
graphs of three to ﬁve serial sections were analyzed.
The number of silver-intensiﬁed immunogold dots
(IG) and the Remak bundle area (determined
using Image J 1.49 t, NIH, USA), comprising
unmyelinated axons and the surrounding Schwann
cell cytoplasm, excluding the Schwann cell nucleus,
were determined. By directly comparing micrographs
of serial sections, it was ensured that gold dots
were not counted twice. Dot density was calculated
as ndots (DR)/area (AR) for each individual
Remak bundle. Since most of the myelinated
ﬁbers surrounding the Remak bundles were thickly
myelinated, presumably MOP-negative ﬁbers, overall
dot density over myelinated ﬁbers (including axon,
myelin sheath, and Schwann cell cytoplasm, exclud-
ing Schwann cell nucleus) was determined as intra-
sectional background labeling. Thereafter, a labeling
enrichment for each Remak bundle was calculated
by dividing its individual dot density value by the
background density value determined in the same
micrographs, and a mean labeling enrichment was
calculated for the Remak bundles analyzed in each
preparation (between 10 and 15).
Western blotting
Rat and mouse tissues were homogenized in radioim-
munoprecipitation assay (RIPA) buﬀer (25mM
HEPES pH 7.6, 2mM EDTA, 25mM NaF, 1% (v/v)
SDS) containing protease inhibitors (Complete; Roche
Applied Science, Mannheim, Germany) and centri-
fuged at 10,000 r/min for 10min at 4C.17,29 Protein
concentration in the supernatant was determined
using bicinchoninic acid (BCA) protein assay
(Thermo Scientiﬁc, Rockford, IL, USA, Pierce BCA
Protein Assay Kit). Fifty (brain and spinal cord) or
100 mg (DRG and sciatic nerve) protein in RIPA w/o
complete and Laemmli buﬀer were denatured at 95C
for 5min, fractionated on sodium dodecyl sulfate poly-
acrylamide gels, and subsequently blotted on nitrocel-
lulose membranes (GE Healthcare UK,
Buckinghamshire, UK). Proteins were detected using
the speciﬁc antibodies against MOP and mcherry (see
above). As protein loading control b-actin (Sigma-
Aldrich) was used. Chemiluminescence signal detection
of bands was acquired with an Imager (Alpha
Innotech, Santa Clara, CA, USA; FluorChem FC2
Imaging systems, Multilmage II).
CGRP release
Sciatic nerves from Wistar rats, sacriﬁced in an atmos-
phere of increasing CO2 concentration, were prepared
as described before including removal of the nerve
sheaths (epi-perineurium).17 Nerves were loosely
wrapped around acrylic glass rods30 and placed in syn-
thetic interstitial ﬂuid (SIF31) containing (in mM) NaCl
108, KCl 3.48, MgSO4 3.5, NaHCO3 26, NaH2PO4 1.7,
CaCl2 1.5, sodium gluconate 9.6, glucose 5.5, and
sucrose 7.6 continuously gassed with carbogen (95%
O2, 5% CO2) to pH 7.4. All experiments were per-
formed in a shaking bath at constant 37C and accord-
ing to a speciﬁc application scheme. This involved
several incubation steps in test tubes containing SIF
or test solutions lasting for 5min each. After a washout
period of 30 min, nerves were incubated as a ﬁrst step
in SIF to determine basal CGRP release. One group
of preparations in the second step was preincubated
with opioids alone or together with the MOP antagon-
ist naloxone. Chemical stimulation with 60mM potas-
sium chloride in the presence of opioids and þ/
naloxone occurred either in the third or fourth incuba-
tion step. This was followed by two incubations or
one, respectively, in SIF to assess reversibility of stimu-
lated CGRP release. The CGRP content of each
obtained ﬂuid sample was determined using a commer-
cial enzyme immunoassay kit (Bertin Pharma,
Montingy le Bretonneux, France). The EIA plates
were measured photometrically using a microplate
reader (Dynatech, Channel Islands, UK).
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Measurement of mechanical nociceptive thresholds
In male Wistar rats, the right sciatic nerve was located
using a 22-gauge needle connected to a nerve stimulator
(Stimuplex Dig RC; Braun) under brief isoﬂurane anes-
thesia as previously described.17 DAMGO, and naloxone
hydrochloride dehydrate (#N7758 and #E7384, Sigma-
Aldrich, St. Louis, MO, USA), as well as fentanyl
(Janssen Cilac, Neuss, Germany) were injected perineu-
rially as described in detail before.17,32 In selected experi-
ments, 300l of 10% NaCl was injected before fentanyl
injection. The doses of fentanyl and DAMGO applied
perineurially have been previously shown not to elicit
systemic eﬀects.33
Mechanical nociceptive thresholds of rats were deter-
mined before and 10min after opioid injection (with or
without 10% NaCl) using the paw pressure algesiometer
(modiﬁed Randall-Sellito test; Ugo Basile, Comerio,
Italy).34 Pressure was applied using a blunt piston onto
the dorsal surface of the hindpaw. The paw pressure
threshold (weight, g) was deﬁned as the pressure required
eliciting paw withdrawal. The average of three measure-
ments was calculated. Treatments were randomized and
blinded.
-Arrestin, MOP constructs, and cell culture
We used bovine b-arrestin-2 fused C-terminally to YFP,
GRK235 as well as human MOP-CFP23 for a triple trans-
fection as described previously. HEK-293 cells were
maintained in Dulbecco’s modiﬁed Eagle medium with
4.5 g/l glucose, 10% fetal calf serum, 100 U/ml penicillin
G, and 100 mg/ml streptomycin sulfate at 37C, 7% CO2.
Individual 24-mm glass coverslips were placed in six-
well plates and coated for 20min using 300l of poly-D-
lysine (1mg/ml). Poly-D-lysine was aspirated, and the
glass coverslips were washed once with sterile PBS with-
out Ca2þ. HEK-293 cells were seeded onto these cover-
slips resulting in approximately 40% conﬂuence. The
cells were transfected using Eﬀectene according to the
manufacturer’s instructions with the following amounts
of DNA for a six-well plate: 2.6mg for hMOP-CFP,
0.5 mg for b-arrestin-2-YFP, and 1.0mg for GRK2. All
constructs were in pcDNA3. Medium was exchanged
24 h later, and cells were analyzed 48 h after transfection.
For measurements in the presence of dynasore (Sigma
Chemical), cells were incubated with 80 mM dynasore
(dissolved in 0.4% DMSO) for 30min prior to ligand
application at 37C, 7% CO2. For experiments with hyper-
tonic saline, cells were incubated with 200mM NaCl for
5min at room temperature prior to measurements.
Confocal microscopy of cell cultures
All confocal microscopy experiments were performed on
a Leica TCS SP8 scanning microscope (Leica, Wetzlar,
Germany). Coverslips with transfected HEK-293 cells
were mounted using an ‘‘Attoﬂuor’’ holder (Molecular
Probes, Eugene, Oregon, USA). Images were taken with
a 63 1.40 Oil objective lens as described previously.36
In brief, using the manufacturer’s settings, CFP was
excited with a 442-nm diode laser, and emission was
detected from 450–505 nm using a Hybrid Detector.
YFP was excited with the 514-nm line of the argon
laser, and emission was detected with the
Photomultiplier from 530–600 nm. Settings for recording
images were kept constant: 512 512-pixel format, line
average 4, frame average 2400Hz. Merely, the gain and
oﬀset were adjusted for each measurement. Time series
were recorded using the standard Leica software package
(version 2.61). Pictures were taken at 15 s intervals for
10min.
Quantiﬁcation of b-arrestin-2-translocation was per-
formed with the Leica Application Suite Advanced
Fluorescence software package (LAS AF version
4.0.0.11706). Regions of interest (ROIs) were deﬁned in
the cytosol and quantiﬁed over the time recorded. Care
was taken that slight movements of the cells did not
result in misplacement of the deﬁned ROIs either onto
the membrane or into the nuclear region. To correct for
possible photobleaching, control regions were deﬁned
that included whole cells and were used to correct the
images in the cytosolic ROIs. To quantify b-arrestin-2-
translocation, the resulting ﬂuorescence intensity values
were normalized to the initial value and plotted against
time.
Statistical analysis
Statistical analysis was done using SigmaPlot 11.0, Systat
Software Inc. In case of not normally distributed data,
the test was performed on ranks. Data are displayed as
mean SEM (pain behavior, CGRP release, b-arrestin
recruitment) or median and percentiles (immunogold
labeling analysis). If aliquots of one sample were exposed
to diﬀerent conditions or repeated measurements (RMs)
from one animal were taken, one- or two-way RMs ana-
lysis of variance was used. Post hoc comparisons were
performed by Bonferroni (behavior data), Scheﬀe post
hoc test (CGRP release), or Dunn’s test on ranks (immu-
nogold quantiﬁcation). Diﬀerences were considered
signiﬁcant if p< 0.05.
Results
Immunolabeling with antibody providing high
specificity and reproducibility indicates MOP
localization in intact rat peripheral nociceptive axons
Immunoﬂuorescence labeling of rat brain sections using
rabbit and guinea pig polyclonal antibodies resulted in
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consistently reproducible labeling patterns known from
the literature on MOP localization in the CNS, e.g. in the
paracapsular intercalated nuclei (Ic) of the amygdala.37
Signal-to-noise ratio was higher for the rabbit (MOP_1,
MOP_2; Figure 1(a)) than for the guinea pig antibodies
(not shown). In the rat DRG, the diﬀerent antibodies
displayed varying and often inconsistent labeling pat-
terns (not shown). Immunoﬂuorescence labeling in the
sciatic nerve was recognized in numerous ﬁbers and
ﬁber bundles, many of which were also positive for cal-
citonin gene-related peptide (CGRP), a marker for sen-
sory axons. However, signiﬁcant ﬂuorescence signal was
always present also in non-CGRP-immunoreactive (ir)
structures, among them apparently numerous Schwann
cells (Figure 1(b)). Control sections incubated without
primary antibodies were devoid of ﬂuorescence signal.
Immunoﬂuorescence labeling using a monoclonal
rabbit MOP-antibody (RabMAb-MOP) yielded speciﬁc
and reproducible staining both in CNS areas (Ic, super-
ﬁcial laminae I/II of dorsal horn of spinal cord) and in
small/medium DRG neurons (Figure 2(a)). In longitu-
dinal sections of sciatic nerves (Figure 2(b)), MOP
immunoreactivity was faint but clearly recognizable,
often granular in appearance, and was localized to
narrow ﬁbers and ﬁber bundles. In phase contrast,
these were situated between groups of large, myelinated
non-reactive ﬁbers (not shown). Dual labeling conﬁrmed
that CGRP was colocalized in all MOP-ir ﬁbers and ﬁber
bundles, providing evidence of MOP localization exclu-
sively in sensory axons. Diﬀerential relative immuno-
ﬂuorescence intensities for MOP and CGRP in ﬁbers
and the presence of solely CGRP-ir ﬁbers in double
labeling both suggested preferential expression of MOP
in subsets of sensory axons. No ﬂuorescence signals were
seen in non-CGRP-ir structures, e.g. Schwann cells, and
control sections again were completely devoid of ﬂuor-
escence signals. RabMAb-MOP detected a signal in
Western blot at the predicted size in the rat brain and
spinal cord (Figure 2(c)). Substantially less MOP protein
was observed in the DRG and the sciatic nerve. In add-
ition, other smaller and larger bands were seen in the
peripheral nervous tissue, which could be due to post-
translational modiﬁcation.38
MOP-mcherry detection in MOP-mcherry knock-in
mice validates localization of the fusion protein in
mouse peripheral nociceptive axons
Mcherry ﬂuorescence signal, enhanced with anti-mcherry
(DsRed) antibody, was speciﬁcally localized in the
Figure 1. MOP-immunolabeling in rat amygdala and sciatic nerve using polyclonal antibodies. Rabbit polyclonal anti-MOP antibodies
(MOP_1 and MOP_2) were used to label cryosections of brain and sciatic nerve. Specific MOP immunoreactivity was observed in (a) the
paracapsular intercalated nuclei (Ic) of the amygdala. Inset shows lack of labeling in control section. Scale bars 100 mm. (b) In MOP_2-CGRP
double-labeled longitudinal sections of sciatic nerves, CGRP-ir fibers/fiber bundles are labeled for MOP (arrowheads), but there are also
numerous fluorescent signals outside CGRP-ir structures, which often, using DAPI couterstaining, are seen to contain nuclei and possess
typical Schwann cell morphology (arrows and inset in upper image). Scale bar 50mm.
BLa: basolateral amygdaloid nucleus; ir: immunoreactive; MOP: m-opioid receptor; CGRP: calcitonin gene-related peptide;
DAPI: 40,6-diamidino-2-phenylindole.
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amygdala, in lamina I and II of the dorsal horn in the
spinal cord and in small/medium-sized neurons of DRG
(Figure 3(a)) in MOP-mcherry knock-in mice. Double
labeling of knock-in mouse sciatic nerve preparations
with anti-mcherry and anti-CGRP conﬁrmed the pres-
ence of MOP-mcherry exclusively in CGRP ﬁbers and
ﬁber bundles (Figure 3(b)). MOP-mcherry immuno-
ﬂuorescence appeared more evenly distributed and less
granular than MOP-immunoﬂuorescence in the rat
samples (see above). This was mainly due to a higher
detection sensitivity of the system, since after UV-light-
induced bleaching, intraaxonal ﬂuorescent granules
became detectable. Immunolabeling on WT mouse
tissue was devoid of ﬂuorescence in all analyzed tissues
(data not shown). In Western blot, we detected MOP-
mcherry (predicted size 80 kDa) in brain, spinal cord,
DRG, and sciatic nerve samples (Figure 3(c)), albeit
with less protein and smaller and larger bands in the
peripheral nervous tissue.38
Immunoelectron microscopic analyses indicate
membrane localization of MOP in nociceptive axons
According to the results of the immunoﬂuorescence
experiments, detection of MOP using RabMAb-MOP
in rat and of mcherry in MOP-mcherry knock-in mice
Figure 2. MOP-immunolabeling using a monoclonal antibody. Cryosections of amygdala, spinal cord, DRG, and sciatic nerve were
incubated with RabMAb-MOP. MOP immunoreactivity was prominent in (a) the Ic of the amygdala (arrows, left panel), in superficial laminae
I/II of spinal dorsal horn (middle panel) and in small/medium DRG neurons (arrows in right panel). Scale bars 100mm. Controls (omission of
the primary Ab) are displayed in the upper left corner (nuclei of the amygdala: CEA: central nucleus; La: lateral nucleus; BLa: basolateral
nucleus). (b) Longitudinal sciatic nerve sections were stained with RabMAb-MOP (red) and the sensory fiber marker CGRP (green).
Arrowheads and open arrows point to fibers/fiber bundles with comparatively high and low MOP immunoreactivity, respectively. Closed
arrows point to fibers containing only CGRP (scale bar 20 mm). (c) Tissue lysates from rat brain (B), spinal cord (SC), DRG, and sciatic
nerve (SN) were separated by electrophoresis, blotted, and reacted using RabMAb-MOP (70 kDa) and b-actin (42 kDa) (all representative
images, n¼ 3).
MOP: m-opioid receptor; DRG: dorsal root ganglion; CGRP: calcitonin gene-related peptide; Ic: intercalated nuclei.
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provides the high detection speciﬁcity, sensitivity, and
reproducibility required for reliable immunoelectron
microscopic analyses of subcellular receptor distribu-
tion. Therefore, preembedding immunogold labeling
was carried out on rat sciatic nerve using RabMAb-
MOP (not shown) and on MOP-mcherry knock-in
mouse sciatic nerve using mcherry antibody (Figure
4(a)). Ultrastructural analysis showed discrete silver-
enhanced immunogold dots (IG) localized on Remak
bundles containing tightly clustered axonal proﬁles sur-
rounded by thin Schwann cell processes. Close inspec-
tion documented MOP/MOP-mcherry localization in
the cytoplasm as well as at the membrane of
unmyelinated axons. Silver-gold-dots were also occa-
sionally seen on presumably non-nociceptive large mye-
linated axons, Schwann cell cytoplasm, and endoneurial
tissue, as well as in control preparations (see below),
indicating some unspeciﬁc labeling. Unspeciﬁc binding
appeared overall higher in the RabMAb-MOP-reacted
rat nerve sections than in the mouse preparation (not
shown). Therefore, we decided to validate the ultra-
structural localization analyses by diligent comparative
analysis of preparations treated with/without mcherry
antibody of MOP-mcherry knock-in and WT mouse
sciatic nerve (MOP-mcherry-pos, MOP-mcherry-neg;
WT-pos, WT-neg). In the MOP-mcherry-pos
Figure 3. MOP-mcherry immunodetection in knock-in mice. (a) Immunolabeling in cryosections is shown in amygdala (left panel),
superficial laminae I/II of spinal dorsal horn (middle panel), and small/medium DRG neurons (right panel). Controls testing for unspecific
antibody binding are inserted in the upper left corner (scale bars 100 mm, nuclei of the amygdala: CEA: central nucleus; La: lateral nucleus;
BLa: basolateral nucleus; Ic: intercalated nuclei). (b) Longitudinal section of MOP-mcherry knock-in sciatic nerve labeled for colocalization
of MOP-mcherry (red) with CGRP (green) in putative nociceptive fibers and fiber bundles (arrowheads: high MOP-mcherry immunor-
eactivity; open arrow: low MOP-mcherry immunoreactivity; closed arrows: CGRP-ir only, scale bar 20mm). (c) Western blots on tissues
from MOP-mcherry mice confirm MOP-mcherry (80 kDa) localization in brain (B), spinal cord (SC), DRG, and sciatic nerve (SN) relative to
b-actin (42 kDa) (all representative images, n¼ 3).
MOP: m-opioid receptor; DRG: dorsal root ganglion; CGRP: calcitonin gene-related peptide.
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Figure 4. Ultrastructural immunolocalization of MOP-mcherry fusion protein in unmyelinated axons. (a) Ultrathin sections from sciatic
nerve of MOP-mcherry knock-in (upper panel) and WT (lower panel) mouse incubated with mcherry antibody (MOP-mcherry-pos, WT-
pos) or without primary antibody (MOP-mcherry-neg, WT-neg) and embedded in Epon. Black and white arrowheads in the inset point to
silver-enhanced immunogold dots (IG) localized at the plasma membrane and in the cytoplasm of unmyelinated axons (ua) of Remak
bundles (R), respectively, in the MOP-mcherry-pos preparation. IG on Remak bundles and myelinated fibers in the controls (WT-pos,
MOP-mcherry-neg, WT-neg) represent unspecific labeling. The arrow in MOP-mcherry-pos points to presumably unspecific label in a
Schwann cell (SC) (a: axon; m: myelin sheath). Scale bar 1 mm. (b) Quantification of immunogold dot distribution comparing the four
experimental conditions is displayed as median (plus 25/75 percentile) dot density enrichment in Remak bundles over background (-fold)
(n¼ 10–15; one-way ANOVA and post hoc Dunn’s test on ranks; *p< 0.05, **p< 0.01).
MOP: m-opioid receptor; WT: wild-type; ANOVA: analysis of variance.
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preparation, the dot density over Remak bundles was
signiﬁcantly higher than background with median label-
ing enrichment (dot density over Remak bundles
divided by dot density over myelinated ﬁbers) of 10.6-
fold (Figure 4(b)). MOP-mcherry immunoreactivity in
small, thinly myelinated nociceptive Ad-ﬁbers was not
speciﬁcally assessed since these ﬁbers could not be
unequivocally identiﬁed in the preparations. Thus,
although background was determined mainly over
large thickly myelinated ﬁbers, labeling enrichment
over Remak bundles may have even been underesti-
mated due to inclusion of some speciﬁc labeling in the
background counts.
To avoid bias due to diﬀerential unspeciﬁc binding
properties of various tissue components, dot density in
Remak bundles over background was determined also in
the controls (MOP-mcherry-neg, WT-pos, WT-neg). The
results here indeed indicated a higher dot density
in Remak bundles compared to myelinated ﬁbers
(possibly caused by lower unspeciﬁc binding aﬃnity
of myelin). However, the medians of labeling enrichment
in Remak bundles were only between 2.1- and 3.2-fold
and were signiﬁcantly lower than in MOP-mcherry-
pos for all controls (Figure 4(b)). This suggests that
the localization of the majority of a signiﬁcant propor-
tion of gold dots in unmyelinated axons (membrane
and cytoplasm) in the MOP-mcherry-pos preparation
speciﬁcally represents the subcellular localization of
the fusion protein. Thus, the ultrastructural analysis
indicates a membrane localization of MOP in unmyeli-
nated (presumably nociceptive) axons of intact sciatic
nerve.
Fentanyl and DAMGO inhibit depolarization-induced
CGRP release from rat nerve axons
Isolated preparations of desheathed sciatic nerves can be
stimulated to release CGRP by depolarization with
potassium chloride.30 To further assess functionality of
axonal MOP, we tested whether opioids could inhibit
CGRP release ex vivo. Treatment of desheathed nerves
with both the hydrophilic opioid DAMGO (10mM)
and the lipophilic opioid fentanyl (1 mM) inhibited
CGRP release stimulated by 60mM potassium chloride
(Figure 5(a) and (b)). Neither opioid alone had any
eﬀect on baseline CGRP release. DAMGO- or fenta-
nyl-mediated inhibition of KCl-induced CGRP release
was essentially absent if the MOP antagonist naloxone
was added in equimolar concentrations (Figure 5(c)
and (d)).
Further studies with fentanyl at diﬀerent concentra-
tions demonstrated that at least 100 nM are required for
a signiﬁcant inhibition of CGRP release stimulated by
potassium chloride-evoked depolarization and EC50 was
estimated to 630 nM (Figure 5(e)). Therefore, we
conclude that functional MOPs are expressed in the
axons of peptidergic primary aﬀerent neurons.
Functionality of axonal MOP in vivo: Behavioral
analysis after perisciatic fentanyl application
We have previously shown that hydrophilic opioid
DAMGO (30 mg) does not increase mechanical nocicep-
tive thresholds unless it is injected together with hyper-
tonic saline (Figure 6(a)).17 As demonstrated before,
opioid-induced increases in mechanical nociceptive
thresholds were speciﬁcally mediated by opioid receptors
because the eﬀect was completely reversed by coinjection
of the MOP antagonist naloxone at concentrations
as low as 0.1 ng (Figure 6(b)).17 The antinociception-
enhancing eﬀect of hypertonic saline is presumably at
least partly dependent on the opening of the perineurial
barrier to allow for the access of DAMGO. However,
since further eﬀects of hypertonicity on the axons cannot
be excluded, we wanted to assess whether axonal MOPs,
which according to our ultrastructural study may be con-
stitutively localized in nociceptive axonal membranes,
are functional under completely physiological condi-
tions. Therefore, we here asked whether perisciatic injec-
tion of the lipophilic opioid fentanyl, which can pass
freely through the perineurial barrier, induces antinoci-
ception by itself. Application of 0.1mg fentanyl signiﬁ-
cantly increased paw pressure thresholds (Figure 6(c)).
A lower dose of fentanyl (0.01 mg) had no impact on
mechanical nociceptive thresholds unless it was coin-
jected with hypertonic saline, indicating an additional
eﬀect of hypertonic saline on axonal MOP availability
and functionality independent of barrier opening.
Opioid-induced increases in nociceptive thresholds were
completely reversed by simultaneous application of the
MOP antagonist naloxone (Figure 6(d)). No change in
paw pressure thresholds was seen in the contralateral
paw indicating no systemic eﬀect. Collectively, these
data reveal that MOP is present and functional in com-
pletely intact nociceptive axons. Hypertonic saline treat-
ment further enhances the function of axonal MOP
in vivo.
Hypertonicity decreases MOP agonist-induced
receptor internalization
Sucrose can block enkephalin- or etorphine-induced
MOP internalization.24 Thus, we hypothesized that
hypertonic saline-induced enhancement of opioid
action in vivo could be mediated by decreased internal-
ization of receptors. To this end, we used a cellular
system to visualize b-arrestin-2 recruitment using
human embryonic kidney (HEK)-293 cells transfected
with b-arrestin-2-yellow ﬂuorescent protein (YFP) and
human MOP-cyan ﬂuorescent protein (CFP).
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Figure 5. Opioids inhibit potassium-induced CGRP release from rat sciatic nerves via MOP. Desheathed sciatic nerves isolated from rats
were preincubated with DAMGO (10 mM, a, n¼ 8), fentanyl (1mM, b, n¼ 4), and each together with the opioid receptor antagonist
naloxone (10mM, c, and 1mM, d, respectively) for 5 min. In the presence of the opioids, CGRP release was induced with 60 mM KCl
(shed gray area). (e) Percent inhibition of KCl-responses was tested at different concentrations of fentanyl (10 nM–100 mM, n¼ 4–8) and
the corresponding EC50 was calculated by fitting to the Boltzmann equation. Naloxone was tested at equimolar concentrations against
fentanyl 0.1 and 1mM, which is indicated by downward arrows (*p< 0.05 calculated by one-way ANOVA with Scheffe´ post hoc test). Data
are presented as means SEM.
MOP: m-opioid receptor; DAMGO: [D-Ala2, N-MePhe4, Gly-ol]-enkephalin; CGRP: calcitonin gene-related peptide; ANOVA: analysis of
variance.
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Treatment with DAMGO reduced the intensity of the b-
arrestin-2 signal in the cytosol by 35% within 120 s con-
sistent with a recruitment of b-arrestin-2 to the mem-
brane after MOP activation. This initial receptor/
b-arrestin-2 interaction initialized internalization of
DAMGO-MOP and over time the complex dissociated.
Cytosolic b-arrestin-2 increased again and a punctuate
pattern of internalized MOP-CFP could be seen
(Figure 7(a) and (d)). Pretreatment with 200mM NaCl
for 5min did not inﬂuence initial b-arrestin-2 recruit-
ment to the membrane but prevented the subsequent
increase in the cytosolic b-arrestin-2 signal,
indicating an inhibition of the internalization of the
DAMGO-MOP b-arrestin-2 complex by hypertonicity
(Figure 7(b) and (d)). To verify the involvement of dyna-
min as a complex to regulate clathrin-induced internal-
ization of MOP, cells were treated with dynasore.39
This treatment again had no eﬀect on b-arrestin recruit-
ment to the membrane but also prevented internalization
of the DAMGO-MOPb-arrestin complex (Figure 7(c)
and (d)).
Next, we also evaluated the eﬀect of fentanyl on
b-arrestin-2 recruitment and internalization. Similar to
DAMGO, fentanyl application reduced the intensity of
the b-arrestin-2 signal in the cytosol by 30% compatible
with rapid b-arrestin-2 recruitment (Figure 7(e) and (h)).
Subsequently, the signal reappeared consistent with an
internalization of the MOP as seen by the punctuate
Figure 6. Perineurial application of the MOP agonists, DAMGO and fentanyl, increase mechanical nociceptive thresholds-improved
function in the presence of hypertonic saline. Wistar rats were injected at the sciatic nerve with DAMGO (30 mg, a) or fentanyl in two
different doses (0.01 or 0.1 mg, c) together with hypertonic (10% NaCl) or normal saline (0.9% NaCl). (b, d) In selected experiments,
DAMGO and fentanyl were applied together with the opioid receptor antagonist naloxone. In all experiments, paw pressure thresholds
were measured right before (‘‘basal’’) and 10 min (‘‘treated’’) after application of DAMGO or fentanyl (all n¼ 6, two-way ANOVA,
Bonferroni post hoc correction, *p< 0.05). Data are presented as means SEM.
MOP: m-opioid receptor; DAMGO: [D-Ala2, N-MePhe4, Gly-ol]-enkephalin; ANOVA: analysis of variance.
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Figure 7. MOP agonist-mediated b-arrestin-2 recruitment: Inhibition of cytosolic b-arrestin-2 reappearance and thereby MOP
internalization by hypertonic saline. (a to c, e to g) Images from HEK-293 triple transfected with MOP-CFP (cyan, upper row), GRK2, and
b-arrestin-2-YFP (yellow, lower row) are shown at 0, 120, or 780 s after application of 100M DAMGO (a to c) or 30M fentanyl (e–g).
Cells were preincubated with 200 mM NaCl for 5 min (b, f) or with 80mM dynasore for 30 min (c, g) followed by application of DAMGO or
fentanyl (representative examples; arrows: membrane b-arrestin-2; scale bars¼ 10 mm). (d, h) Images were quantified and corrected for
photobleaching as described under ‘‘Material and Methods’’ Black squares (DAMGO or fentanyl), red circles (preincubation with dynasore
followed by DAMGO or fentanyl), blue triangles (preincubation with 200 mM NaCl followed by DAMGO or fentanyl) (DAMGO: n¼ 42
cells, 22 cells, or 25 cells, respectively; fentanyl: n¼ 31 cells, 22 cells, or 20 cells, respectively, all six to nine different experiments, at least
three different transfections).
DAMGO: [D-Ala2, N-MePhe4, Gly-ol]-enkephalin; YFP: yellow fluorescent protein; MOP-CFP: m-opioid receptor-cyan fluorescent protein;
HEK: human embryonic kidney; GRK2: G protein-coupled receptor kinase 2.
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pattern of internalized MOP-CFP, which was inhibited if
cells were pretreatedwith hypertonic saline (Figure 7(f) and
(h)). Dynasore did not inhibit internalization of fentanyl-
MOPb-arrestin complex (Figure 7(g) and (h)), while b-
arrestin-2 started to accumulate again in the cytosol.
In summary, hypertonic environment attenuates
fentanyl- or DAMGO-induced MOP b-arrestin-2
internalization in an in vitro system.
Discussion
In the present study, we demonstrate by light and elec-
tron microscopic analyses that opioid receptors are pre-
sent at plasma membranes of peripheral sensory axons.
Application of lipophilic opioids at the sciatic nerve
increased mechanical nociceptive thresholds and inhib-
ited CGRP release. Treatment with hypertonic saline
further enhances fentanyl-induced increases in nocicep-
tive thresholds. In recombinant cellular systems, opioids
induced b-arrestin-2 recruitment and subsequent MOP
internalization. This was prevented by hypertonic
stress. This mechanism could increase the availability
of MOP on the cell surface within seconds as a possible
mechanism of enhanced opioid receptor function due to
treatment with hypertonic saline in vivo.
Detection of peripheral axonal opioid receptors
Antibodies against MOP40 and also DOP40,41 have long
been discussed regarding their speciﬁcity in Western
blots and immunohistochemistry. For example,
Schmidt et al.3 observed speciﬁc staining in the brain
and spinal cord but not in the DRG using MOP-
knockout mice as controls. Additionally, MOP immu-
noreactivity is comparatively low in intact sciatic
nerve3,42 so that particularly high signal-to-noise ratio
of the detection is required to enable reliable and repro-
ducible identiﬁcation. Here, we yielded speciﬁc but low-
intensity MOP immunoreactivity in the undamaged rat
sciatic nerve using RabMAb-MOP. Importantly, immu-
noreactions lacked signiﬁcant labeling outside
CGRP-positive ﬁbers and ﬁber bundles. Interestingly,
the relative immunolabeling intensity for MOP and
CGRP diﬀered between individual axons and in axon
bundles, indicating presence of MOP at varying levels
in diﬀerent sensory (e.g. nociceptive) axon types in
naı¨ve rats. Additionally, we veriﬁed our ﬁndings in a
knock-in mouse line expressing MOP fused to the red
ﬂuorescent mcherry protein.25 Our results conﬁrm diﬀer-
ential MOP-localization solely in CGRP-ir sensory ﬁbers
and ﬁber bundles of the sciatic nerve also in mice.
Speciﬁcity of antibody staining is a necessary pre-
requisite for successful detection of subcellular protein
localization using immunoelectron microscopy. The
similarity in light microscopic immunolabeling patterns
documented in the present study for MOP in rat and
mcherry in the knock-in mouse sciatic nerve sciatic
nerve validates that localization of the MOP-mcherry
fusion protein represents the localization of MOP in
the sciatic nerve also in non-genetically modiﬁed ani-
mals. Diligent analyses including several controls sug-
gested that preembedding mcherry-immunolabeling in
mcherry knock-in mouse sciatic nerve represents cell-spe-
ciﬁc subcellular localization of the fusion protein, and
thus of MOP in rodent sciatic nerve. Taken together,
the results indicate that MOP is constitutively present
not only at the nerve terminals but also along the mem-
branes of non-myelinated, presumably nociceptive axons
of sciatic nerves. RabMAb-MOP stainings in rat sciatic
nerves provide lower signal-to-noise ratio, similar to
what was observed in the light microscopical prepar-
ations. However, further methodological improvements
might enable quantitative analysis also of immunoelec-
tron microscopic results using direct MOP labeling.
Functional opioid receptors in axons: Inhibition of
CGRP release and increases in nociceptive thresholds
Binding of opioids to MOP reduces nociceptive signal
transmission at central Ad- and C-ﬁber synapses by
inhibition of presynaptic N-type voltage-dependent
Ca2þ channels. P/Q-type voltage-dependent Ca2þ
channels and the Ca2þ-dependent transmitter release
machinery are also targets of opioids43 especially in the
peripheral nervous system.22 Here, both fentanyl and
DAMGO prevented depolarization-induced CGRP
release from the sciatic nerve in vitro. These results
diﬀer from other studies,44 because morphine and deltor-
phin as a DOP agonist alone could not inhibit depolar-
ization-induced CGRP release from desheathed nerves.
Only the sequential administration of deltorphin and
morphine blocked CGRP release. DAMGO (100 nM)
slightly, but not signiﬁcantly, inhibited KCl-induced
CGRP release. The contrast to our work may be
explained, because substantially lower concentrations
of both MOP agonists were applied and non-desheathed
nerves were used, which prevents penetration of peptides
like DAMGO and CGRP and hinders permeation of
hydrophilic opioids through the intact epi-perineurium.
Evidence of axonal function of opioid receptors was
shown in mice with neuropathic pain after sciatic nerve
ligation.3,9–11 However, the function of opioid receptors
in the absence of neuropathy remains controversial.
Here, we provide evidence that axonal opioid receptors
are functional and increase nociceptive thresholds even
in undamaged nerves, if lipophilic opioids are used.
Opioid-induced antinociception was not an unspeciﬁc
local anesthetic-like eﬀect,45 because it was fully blocked
by naloxone as seen before.17 Treatment with hypertonic
saline further enhanced opioid-mediated antinociception
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as indicated by lower dose of fentanyl necessary to elicit
an eﬀect.
In summary, MOP activation ex vivo reduces stimu-
lated CGRP release from peripheral axons and can
increase nociceptive thresholds, indicating that opioid
receptors, like other receptors important for nocicep-
tive signal transduction, are not solely transported along
the axon but can also be eﬀectively inserted into the axo-
lemma to become functionally competent and couple to
signaling pathways suited to inhibit nociceptor function.
Hypertonic solution: Opioid function in vivo and MOP
internalization in vitro
The behavioral studies indicate that hypertonic saline
treatment induces increased availability and/or function-
ality of MOP in peripheral sensory axons. This could be
due to transient local increase of MOP insertion and
presence in axonal membranes caused possibly via a
local block of axonal transport. An augmented mem-
brane insertion of axonal MOP might lead to extended
opioid eﬀects possibly via decreased receptor desensitiza-
tion. Hypertonic solutions (high concentrations of
sucrose) inhibit internalization of receptors,24,46 but no
studies have been done using hypertonic saline and
MOP. Fentanyl and DAMGO – in contrast to
morphine – both induce internalization of MOP via a
dynamin-mediated process. Dynasore is a small molecule
GTPase inhibitor that targets dynamin-1, dynamin-2,
and dynamin-related protein 1 (Drp1). It blocks
dynamin-dependent endocytosis, because it inhibits the
scission of endocytic vesicles. Here, we used dynasore as
a positive control to prevent dynamin-mediated intern-
alization of MOP after DAMGO activation.
In transfected cells, fentanyl as well as DAMGO
rapidly promoted b-arrestin-2 recruitment to the mem-
brane and subsequent internalization of the complex.
Redistribution of b-arrestin-2 to the cytosol and thereby
internalization was impeded by hypertonic saline.
Dynasore blocked internalization of DAMGO but not
of fentanyl. An explanation could be a less tight complex
formation between fentanyl-MOP/b-arrestin-2 compared
to DAMGO-MOP/b-arrestin-2. DAMGOmediates MOP
phosphorylation at the key residue serine-375 via G pro-
tein-coupled receptor kinase 2 (GRK2) and GRK3,47
while fentanyl mediates MOP phosphorylation at this
site via GRK3.48 This residue needs to be phosphorylated
prior to further phosphorylation on other sites of the
MOP (for a recent review on the complex issue of MOP
phosphorylation, we refer to Allouche et al.49). Since we
only used GRK2 for cotransfection, the endogenous
kinase expression of GRK3 in our HEK cells might be
limiting in the case of fentanyl, which might lead to less
complete phosphorylation pattern of the receptor. Given
that the number of phosphates has been shown to be
important for receptor/arrestin complex aﬃnity,50 this
could be an explanation for this observation.
The diﬀerences observed between treatment with
dynasore and hypertonic solution have to be discussed
in the light of the fact that sodium ions can act as allo-
steric enhancers of ligand aﬃnity at G protein-coupled
receptors (GPCRs) including DOP,51,52 and we used
200mM sodium chloride solution as the hypertonic
stimulus. Indeed, recent data point toward sodium’s
role as a potential cofactor in class A GPCR function.
Nonetheless, hypertonic saline inhibits internalization
of agonist-MOP complexes, which could also be a
mechanism why MOP function is increased after treat-
ment with hypertonic saline. The process remains to be
completely elucidated. Hypertonic treatment causes
coated pits to disappear and induces abnormal clathrin
polymerization.53,54 In conclusion, hypertonic saline pre-
vents receptor internalization or might change the ligand
aﬃnity ultimately leading to improved receptor function.
Conclusion
MOPs are functionally expressed along the membrane of
the peripheral nerve axons and can be targeted by opi-
oids to inhibit nociception in vivo in naive rats and
CGRP release in vitro. Hypertonic saline may increase
MOP membrane availability, which could account for
enhanced MOP function. The immunolabeling protocols
using speciﬁc MOP detection methods developed in the
present study will aid future analyses on peripheral
axonal MOP localization and function.
Opioids can be eﬀective in regional anesthesia in
patients as long as they can penetrate the perineurial
barrier. However, it is worthwhile to further explore
various methods of increasing functionality of MOP
in axons to improve selective targeting of nociceptive
neurons inducing analgesia without impairing motor or
sensory function.
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